MorphoSys, Novartis, Galapagos abandon experimental MOR106

30th October 2019 Uncategorised 0

The decision was based on a “low probability to meet main goal of study.”

More: MorphoSys, Novartis, Galapagos abandon experimental MOR106
Source: News